Kelly Banas is the Associate Director of Research of the Gene Editing Institute. She leads a team of researchers working to identify new clinically relevant genomic targets as well as working to understand the specificity and safety of CRISPR/Cas systems as a therapeutic modality. Her previous research has led to an innovative foundational approach to the treatment of solid tumors using CRISPR-directed gene editing, which is currently being developed for Investigational New Drug status. She received her Ph.D. in 2021 from the University of Delaware, where she studied the short- and long-term effects of CRISPR as a treatment for solid tumors.
